Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin

Tsunehiro Takahashi, Sadako Akashi-Tanaka, Takashi Fukutomi, Toru Watanabe, Noriyuki Katsumata, Kunihisa Miyakawa, Tadashi Hasegawa, Hitoshi Tsuda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages IIA, IIB, IIIA and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital. Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m 2 and docetaxel (Taxotere: DOC) 60 mg/m 2 every three weeks. The overall clinical response to this regimen was 88% (69/78). Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment. One patient had inflammatory breast cancer (IBC) and the other had primary squamous cell carcinoma (SCC) of the breast. There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer.

Original languageEnglish
Pages (from-to)234-237
Number of pages4
JournalBreast Cancer
Volume8
Issue number3
DOIs
Publication statusPublished - 2001 Aug
Externally publishedYes

Fingerprint

docetaxel
Doxorubicin
Inflammatory Breast Neoplasms
Breast Neoplasms
Drug Therapy
Breast
Squamous Cell Carcinoma
Cancer Care Facilities

Keywords

  • Breast cancer
  • Inflammatory breast cancer
  • Neoadjuvant chemotherapy
  • Progressive disease
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Takahashi, T., Akashi-Tanaka, S., Fukutomi, T., Watanabe, T., Katsumata, N., Miyakawa, K., ... Tsuda, H. (2001). Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin. Breast Cancer, 8(3), 234-237. https://doi.org/10.1007/BF02967514

Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin. / Takahashi, Tsunehiro; Akashi-Tanaka, Sadako; Fukutomi, Takashi; Watanabe, Toru; Katsumata, Noriyuki; Miyakawa, Kunihisa; Hasegawa, Tadashi; Tsuda, Hitoshi.

In: Breast Cancer, Vol. 8, No. 3, 08.2001, p. 234-237.

Research output: Contribution to journalArticle

Takahashi, T, Akashi-Tanaka, S, Fukutomi, T, Watanabe, T, Katsumata, N, Miyakawa, K, Hasegawa, T & Tsuda, H 2001, 'Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin', Breast Cancer, vol. 8, no. 3, pp. 234-237. https://doi.org/10.1007/BF02967514
Takahashi, Tsunehiro ; Akashi-Tanaka, Sadako ; Fukutomi, Takashi ; Watanabe, Toru ; Katsumata, Noriyuki ; Miyakawa, Kunihisa ; Hasegawa, Tadashi ; Tsuda, Hitoshi. / Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin. In: Breast Cancer. 2001 ; Vol. 8, No. 3. pp. 234-237.
@article{81f3e9981d1444989041cd610cb42e6d,
title = "Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin",
abstract = "Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages IIA, IIB, IIIA and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital. Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m 2 and docetaxel (Taxotere: DOC) 60 mg/m 2 every three weeks. The overall clinical response to this regimen was 88{\%} (69/78). Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment. One patient had inflammatory breast cancer (IBC) and the other had primary squamous cell carcinoma (SCC) of the breast. There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer.",
keywords = "Breast cancer, Inflammatory breast cancer, Neoadjuvant chemotherapy, Progressive disease, Squamous cell carcinoma",
author = "Tsunehiro Takahashi and Sadako Akashi-Tanaka and Takashi Fukutomi and Toru Watanabe and Noriyuki Katsumata and Kunihisa Miyakawa and Tadashi Hasegawa and Hitoshi Tsuda",
year = "2001",
month = "8",
doi = "10.1007/BF02967514",
language = "English",
volume = "8",
pages = "234--237",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin

AU - Takahashi, Tsunehiro

AU - Akashi-Tanaka, Sadako

AU - Fukutomi, Takashi

AU - Watanabe, Toru

AU - Katsumata, Noriyuki

AU - Miyakawa, Kunihisa

AU - Hasegawa, Tadashi

AU - Tsuda, Hitoshi

PY - 2001/8

Y1 - 2001/8

N2 - Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages IIA, IIB, IIIA and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital. Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m 2 and docetaxel (Taxotere: DOC) 60 mg/m 2 every three weeks. The overall clinical response to this regimen was 88% (69/78). Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment. One patient had inflammatory breast cancer (IBC) and the other had primary squamous cell carcinoma (SCC) of the breast. There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer.

AB - Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages IIA, IIB, IIIA and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital. Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m 2 and docetaxel (Taxotere: DOC) 60 mg/m 2 every three weeks. The overall clinical response to this regimen was 88% (69/78). Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment. One patient had inflammatory breast cancer (IBC) and the other had primary squamous cell carcinoma (SCC) of the breast. There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series. Our observations suggest that this regimen might not be effective for these types of breast cancer.

KW - Breast cancer

KW - Inflammatory breast cancer

KW - Neoadjuvant chemotherapy

KW - Progressive disease

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0035233737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035233737&partnerID=8YFLogxK

U2 - 10.1007/BF02967514

DO - 10.1007/BF02967514

M3 - Article

C2 - 11668246

AN - SCOPUS:0035233737

VL - 8

SP - 234

EP - 237

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 3

ER -